News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Holdings Corp. Prices $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules

February 8, 2021 • 10:30 AM EST

Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity

February 8, 2021 • 7:00 AM EST

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

January 14, 2021 • 7:00 AM EST

Tonix Pharmaceuticals Holdings Corp. Closes $40M Common Stock Offering Priced At-the-Market Under Nasdaq Rules

January 13, 2021 • 4:05 PM EST

Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq Rules

January 11, 2021 • 12:59 PM EST

Tonix Pharmaceuticals to Participate in Upcoming January Conferences

January 5, 2021 • 4:15 PM EST

Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection

January 5, 2021 • 7:00 AM EST

Tonix Pharmaceuticals Plans Commercial Scale Vaccine Manufacturing Facility

December 23, 2020 • 9:00 AM EST

Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin)

December 22, 2020 • 7:00 AM EST

Tonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans

December 21, 2020 • 7:00 AM EST

« Previous
1
2
3
4
5
6
7
8
9
10
...43
Next »

Show All